Home » Dental and oral health » Advanced Existence Sciences second-one fourth net loss reduces to $2.

In which the Company’s $2.0 million promissory note with Dr. Flavin was exchanged for 47,619,047 shares of the Company’s common stock.. Advanced Existence Sciences second-one fourth net loss reduces to $2.1 million Advanced Existence Sciences Holdings, Inc. , a biopharmaceutical business engaged in the discovery, development and commercialization of novel medications in the therapeutic areas of infection, oncology and respiratory diseases, announced its financial outcomes for the next quarter ended June 30 today, 2010. Flavin, Ph.D., chairman and ceo of Advanced Life Sciences. As we broaden our pipeline to handle unmet medical needs in treating life-threatening infections caused by Gram-adverse pathogens, we are pleased to possess partnered with Dr. Robert Hancock and The University of British Columbia to develop novel antibiotics that may augment our inner R&D initiatives in this area.june 30 The net loss allocable to common shareholders for the 90 days ended, 2010 was $2.1 million or per talk about in comparison to a net loss allocable to common shareholders of $2.6 million or per talk about for the 90 days ended June 30, 2009.The submission of this NDA marks a substantial milestone for the APF530 program, our Biochronomer medication delivery technology and A.P. Pharma as a company, said Ronald J. Prentki, A.P. Pharma’s president and chief executive officer. Our number-one concern has been to assemble and submit a total and high-quality NDA. We thank our regulatory, CMC, clinical and e-filing professionals for his or her tireless efforts and look forward to a timely review by the FDA. The good efficacy and protection demonstrated in the APF530 Phase 3 medical program provides a strong basis for our submission, mentioned Mr. Prentki. We believe APF530, which maintains therapeutic drug amounts for five days, will be a ‘long acting’ agent offering essential advantages over anti-emetics presently used in preventing CINV, and would give a particular advantage to those many sufferers suffering with delayed onset vomiting and nausea.